Liver Cirrhosis — Diagnosis and Complications Management
Liver cirrhosis represents the final common pathway of chronic liver injury, diagnosed by FibroScan liver stiffness measurement ≥12.5 kPa or liver biopsy showing Metavir F4 fibrosis, and staged using the Child-Pugh score and MELD/MELD-Na for prognosis and transplant prioritization. First-line management of ascites combines sodium restriction to less than 2 g/day with spironolactone 100 mg PO daily titrated up to 400 mg/day, adding furosemide 40 mg PO daily when needed. Variceal bleeding demands immediate resuscitation with octreotide 50 mcg IV bolus followed by 50 mcg/hr infusion plus urgent endoscopy within 12 hours, with ligation for esophageal varices and tissue adhesive (e.g., N-butyl-cyanoacrylate) for isolated gastric varices and type 2 gastroesophageal varices (GOV2). All patients with compensated cirrhosis require hepatocellular carcinoma surveillance with abdominal ultrasound and serum AFP every 6 months, with transplant evaluation initiated once MELD score reaches 15 or higher.
Pathophysiology
Liver cirrhosis develops through a relentless cycle of hepatocyte injury, chronic inflammation, and progressive fibrosis that ultimately replaces functional hepatic parenchyma with collagen-rich scar tissue. Regardless of the initiating insult — whether alcohol, metabolic dysfunction-associated steatotic liver disease (MASLD/NASH), chronic hepatitis B or C, autoimmune hepatitis, or cholestatic diseases like primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) — the converging pathological pathway involves activation of hepatic stellate cells (HSCs) as the central driver of fibrogenesis. These quiescent vitamin A-storing cells transform into proliferative myofibroblasts under the influence of transforming growth factor-beta (TGF-beta), platelet-derived growth factor (PDGF), and reactive oxygen species released from damaged hepatocytes and activated Kupffer cells.
- Core Mechanism
- Hepatic stellate cell activation and transdifferentiation into myofibroblasts, producing excess extracellular matrix (collagen types I and III) that disrupts hepatic sinusoidal architecture
- Key Pathway
- TGF-beta/Smad signaling drives fibrogenesis; PDGF promotes stellate cell proliferation; NF-kB-mediated inflammation sustains injury cycle; gut-liver axis endotoxemia via portal-systemic shunting amplifies Kupffer cell activation
- Genetic Factors
- PNPLA3 I148M variant (rs738409) increases MASLD-cirrhosis risk 3-fold; TM6SF2 E167K variant; HFE C282Y for hemochromatosis; SERPINA1 for alpha-1 antitrypsin deficiency
- Risk Factors
- MODIFIABLE: alcohol intake >30 g/day (men), >20 g/day (women); obesity (BMI >30); type 2 diabetes; metabolic syndrome | NON-MODIFIABLE: age >50; male sex; HBV/HCV chronic infection; genetic polymorphisms
- Biomarkers
- FIB-4 index (>3.25 suggests advanced fibrosis); APRI score (>2.0 correlates with cirrhosis); ELF (Enhanced Liver Fibrosis) score ≥10.51; serum hyaluronic acid >75 ng/mL; platelet count <150,000/mcL
The progression from fibrosis to established cirrhosis fundamentally alters hepatic hemodynamics. Collagen deposition in the space of Disse obliterates sinusoidal fenestrations, increasing intrahepatic vascular resistance. This structural change, combined with the tonic contractile activity of activated stellate cells and reduced nitric oxide (NO) bioavailability within the liver, produces sinusoidal portal hypertension (hepatic venous pressure gradient, HVPG ≥5 mmHg). As HVPG rises above 10 mmHg (clinically significant portal hypertension), portosystemic collaterals develop, including esophageal and gastric varices. Splanchnic vasodilation, mediated by excess NO in the mesenteric circulation, triggers compensatory activation of the renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system, and non-osmotic vasopressin release — the “underfill theory” that drives sodium and water retention, leading to ascites formation. Progressive hepatocyte loss simultaneously reduces synthetic capacity (albumin, coagulation factors) and metabolic clearance (bilirubin, ammonia), culminating in the clinical hallmarks of decompensated cirrhosis: jaundice, coagulopathy, hepatic encephalopathy, and hepatorenal syndrome.
Diagnostic Protocol
The diagnosis of liver cirrhosis relies on a combination of clinical, laboratory, imaging, and histological findings. Suspect cirrhosis in any patient with chronic liver disease who develops signs of hepatic dysfunction (jaundice, coagulopathy) or portal hypertension (ascites, splenomegaly, varices). Non-invasive assessment with transient elastography (FibroScan) has largely supplanted liver biopsy for initial diagnosis, with a liver stiffness measurement (LSM) ≥12.5 kPa having 87% sensitivity and 91% specificity for detecting cirrhosis (Metavir F4). FIB-4 index above 3.25 and APRI score above 2.0 serve as useful laboratory-based screening tools in settings where elastography is unavailable. Once cirrhosis is established, prognosis and management decisions hinge on two critical scoring systems: the Child-Pugh classification (stratifying functional reserve into classes A, B, and C) and the MELD/MELD-Na score (a continuous variable used for transplant organ allocation). The Baveno VII consensus further refines risk stratification by using LSM and platelet count to identify patients who can safely avoid screening endoscopy for varices — specifically, patients with compensated cirrhosis with LSM <20 kPa and platelet count >150,000/mcL have a very low risk of high-risk varices and do not require screening EGD.
Child-Pugh Classification
| Parameter | 1 Point | 2 Points | 3 Points |
|---|---|---|---|
| Total bilirubin (mg/dL) | <2 | 2–3 | >3 |
| Serum albumin (g/dL) | >3.5 | 2.8–3.5 | <2.8 |
| INR | <1.7 | 1.7–2.3 | >2.3 |
| Ascites | None | Mild (diuretic-responsive) | Moderate-severe (refractory) |
| Encephalopathy | None | Grade I–II | Grade III–IV |
| Class | Score | 1-Year Survival | 2-Year Survival | Clinical Action |
|---|---|---|---|---|
| A (Compensated) | 5–6 | 95% | 90% | HCC surveillance, variceal screening, etiology treatment |
| B (Significant) | 7–9 | 80% | 70% | Complication management, transplant evaluation if MELD ≥15 |
| C (Decompensated) | 10–15 | 45% | 35% | Urgent transplant referral, aggressive complication management |
MELD/MELD-Na Score
The Model for End-Stage Liver Disease (MELD) score uses serum bilirubin, creatinine, and INR to predict 90-day mortality and prioritize transplant allocation. MELD-Na adds serum sodium for improved prognostication. A MELD score ≥15 indicates a survival benefit from liver transplantation. MELD ≥21 carries a 3-month mortality exceeding 20%. The updated MELD 3.0 incorporates sex, albumin, and sodium alongside bilirubin, creatinine, and INR, reducing the disadvantage previously seen in female candidates.
Diagnostic Workup
| Test | Rationale / What It Shows | Sensitivity | Specificity |
|---|---|---|---|
| FibroScan (LSM ≥12.5 kPa) | Non-invasive fibrosis staging; replaces biopsy for most patients | 87% | 91% |
| FIB-4 Index (>3.25) | Lab-based screening: (Age x AST) / (Platelet x ALT^0.5) | 74% | 80% |
| Abdominal ultrasound with Doppler | Nodular liver contour, splenomegaly, ascites, portal flow direction | 82% | 78% |
| Liver biopsy (Metavir F0–F4) | Gold standard for fibrosis staging and etiology confirmation | 95% | 95% |
| APRI (>2.0) | AST-to-Platelet Ratio Index; quick bedside calculation | 65% | 82% |
| EGD (upper endoscopy) | Variceal screening; grade small vs. large; red wale marks | 90% | 95% |
Differential Diagnosis
| Condition | Distinguishing Feature | Key Workup |
|---|---|---|
| Congestive hepatopathy | Dilated IVC and hepatic veins on imaging; elevated JVP; no splenomegaly; AST/ALT mildly elevated with markedly elevated alkaline phosphatase | Echocardiogram, right heart catheterization, hepatic vein Doppler |
| Budd-Chiari syndrome | Acute or chronic hepatic vein thrombosis; caudate lobe hypertrophy; no portal vein thrombosis initially; younger patients with myeloproliferative disorders | Doppler ultrasound of hepatic veins, JAK2 V617F mutation, CT/MR venography |
| Hepatic sinusoidal obstruction syndrome | Post-HSCT or pyrrolizidine alkaloid exposure; painful hepatomegaly, weight gain, and jaundice without portal vein thrombosis; bilirubin rise precedes AST | Hepatic venous pressure gradient measurement, liver biopsy showing central venular occlusion |
| Schistosomiasis-related portal fibrosis | Periportal (Symmer pipe-stem) fibrosis on imaging; preserved hepatic synthetic function despite massive splenomegaly; endemic travel history | Stool ova and parasites, rectal biopsy, abdominal ultrasound for periportal fibrosis pattern |
| Non-cirrhotic portal hypertension (NCPH) | Portal hypertension with normal or near-normal liver stiffness; normal synthetic function; often associated with idiopathic PVT or nodular regenerative hyperplasia | Liver biopsy (no cirrhosis), HVPG measurement, thrombophilia workup |
Treatment Algorithm
Treatment of liver cirrhosis focuses on three pillars: eliminating the underlying etiology to halt fibrosis progression, managing the complications of portal hypertension and hepatic insufficiency, and identifying candidates for liver transplantation. Etiologic treatment includes alcohol abstinence support, direct-acting antivirals for HCV, tenofovir or entecavir for HBV, immunosuppression for autoimmune hepatitis, and ursodeoxycholic acid for PBC. Complication management requires a systematic, stepwise approach addressing ascites, spontaneous bacterial peritonitis (SBP), hepatic encephalopathy, and variceal bleeding as distinct but interconnected targets. The overarching goal is to prevent decompensation in compensated patients and reduce mortality in those already decompensated.
Ascites is the most common complication of decompensated cirrhosis, affecting approximately 60% of patients within 10 years. Start all patients on dietary sodium restriction to less than 2 g/day (88 mEq/day). Initiate diuretic therapy with the aldosterone antagonist spironolactone as first-line, titrating upward every 3–5 days while monitoring potassium and creatinine. Add furosemide for patients with inadequate response or when potassium exceeds 5.5 mEq/L. For tense ascites, perform large-volume paracentesis (LVP) with intravenous albumin replacement to prevent post-paracentesis circulatory dysfunction. Grade A
Spironolactone (Aldactone): 100 mg PO daily, titrate by 100 mg every 3-5 days, max 400 mg/day
Furosemide (Lasix): 40 mg PO daily, titrate by 40 mg every 3-5 days, max 160 mg/day
Albumin replacement post-LVP: Albumin 25% 8 g per liter of ascites removed (if >5 L removed)
SBP prophylaxis: Norfloxacin 400 mg PO daily or Ciprofloxacin 500 mg PO daily
SBP treatment: Ceftriaxone 2 g IV daily x 5-7 days (first-line for community-acquired SBP in countries with low rates of bacterial resistance) plus Albumin 1.5 g/kg IV on day 1, then 1 g/kg IV on day 3 Grade A
Other SBP settings: in countries with high rates of bacterial resistance, consider piperacillin/tazobactam or a carbapenem. Healthcare-associated and nosocomial SBP is more likely to harbor antibiotic resistance: give piperacillin/tazobactam in areas with a low prevalence of multidrug resistance and a carbapenem in areas with a high prevalence of ESBL-producing Enterobacteriaceae, combining the carbapenem with a glycopeptide, daptomycin or linezolid in areas with a high prevalence of gram-positive multidrug-resistant bacteria. In all SBP settings, give albumin 1.5 g/kg IV at diagnosis (day 1), then 1 g/kg IV on day 3.
In compensated cirrhosis, patients who are not on non-selective beta-blockers require variceal screening via EGD unless they meet Baveno VII low-risk criteria (LSM <20 kPa and platelets >150,000/mcL); patients with ascites who are not on propranolol, nadolol or carvedilol should undergo screening EGD. For primary prophylaxis of variceal bleeding, initiate non-selective beta-blocker (NSBB) therapy in patients with medium or large varices, or small varices with red wale signs. Carvedilol is preferred for primary prophylaxis due to superior portal pressure reduction. For acute variceal hemorrhage, initiate vasoactive therapy immediately and perform emergent endoscopy within 12 hours: endoscopic variceal ligation (EVL) for esophageal varices, EVL or tissue adhesive for type 1 gastroesophageal varices (GOV1), and endoscopic therapy with tissue adhesive (e.g., N-butyl-cyanoacrylate) for isolated gastric varices and type 2 gastroesophageal varices (GOV2) that extend beyond the cardia. In patients bleeding from esophageal varices or GOV1, preemptive PTFE-covered TIPS within 72 hours is indicated when they meet the high-risk criteria (listed under Non-Responder below). For bleeding from GOV2 or type 1 isolated gastric varices (IGV1), Baveno VIII (2026) describes two treatment phases that may start in parallel: immediate hemostasis, which can be achieved with endoscopic cyanoacrylate injection or EUS-guided therapy, and definitive treatment, for which TIPS with or without variceal embolization, performed as soon as possible, is the preferred option; when TIPS is contraindicated, other definitive strategies, such as transvenous obliteration, endoscopic therapies or surgical methods, may be used depending on available expertise and after multidisciplinary discussion. Failure to control variceal bleeding despite combined pharmacological and endoscopic therapy is best managed by salvage PTFE-covered TIPS. Outside acute variceal bleeding, TIPS is reserved for recurrent or refractory ascites and recurrent variceal bleeding despite optimal endoscopic and pharmacological therapy. Grade A
Carvedilol (Coreg): 6.25 mg PO daily, titrate to 12.5 mg PO daily (max for portal HTN) Grade B
Propranolol (Inderal): 20 mg PO BID, titrate to resting HR 55-60 bpm, max 320 mg/day
Nadolol (Corgard): 40 mg PO daily, titrate to resting HR 55-60 bpm, max 160 mg/day
Octreotide (Sandostatin) for acute bleed: 50 mcg IV bolus, then 50 mcg/hr continuous infusion x 3-5 days
Empiric antibiotics with acute bleed: Ceftriaxone 1 g IV daily x 7 days Grade A
Hepatic encephalopathy (HE) affects 30–45% of cirrhotic patients and significantly worsens quality of life and survival. Management centers on reducing ammonia production and absorption while correcting precipitants (infection, GI bleeding, constipation, electrolyte imbalances, sedative use). Lactulose is the first-line agent, titrated to achieve 2–3 soft bowel movements per day. Add rifaximin for secondary prophylaxis after the first episode of overt HE, as the combination reduces recurrence by approximately 50% compared to lactulose alone. Liver transplantation remains the only definitive treatment for decompensated cirrhosis and should be evaluated for all patients with MELD ≥15, recurrent HE despite medical therapy, or any single episode of SBP, HRS, or refractory ascites. Grade A
Lactulose (Enulose): 15-30 mL PO BID-TID, titrate to 2-3 soft stools/day
Rifaximin (Xifaxan): 550 mg PO BID (continuous, for secondary prophylaxis)
Lactulose enema for acute HE: 300 mL in 700 mL water PR, retain 30-60 min, repeat q4-6h
Non-pregnant adults
Cirrhosis complications
If ascites with SAAG ≥1.1 g/dL
Then
- Sodium <2 g/day; start spironolactone 100 mg daily (≥65 y: 50 mg; avoid if CrCl <30 mL/min); add furosemide 40 mg daily if recurrent or poor response
- Tense: LVP + IV albumin 8 g/L removed if >5 L; refractory: serial LVP, evaluate for TIPS
If suspected variceal bleeding
Then
- Now: octreotide 50 mcg IV, then 50 mcg/h for 3‑5 days; ceftriaxone 1 g IV daily
- Transfuse to Hb 7‑8 g/dL; higher if cardiovascular disease
- Endoscopy ≤12 h: EVL; isolated gastric or GOV2: cyanoacrylate
If bleeding is uncontrolled, high risk, or from GOV2 or IGV1
Then
- Salvage covered TIPS if drugs and endoscopy fail
- Pre‑emptive covered TIPS ≤72 h (esophageal or GOV1): Child‑Pugh C 10‑13, or B >7 actively bleeding at EGD
- GOV2/IGV1: definitive TIPS ± embolization ASAP (preferred)
If overt hepatic encephalopathy
Then
- Correct precipitants
- Lactulose, titrated to 2‑3 soft stools/day; avoid overuse
If MELD ≥15, decompensation or HCC confined to the liver
Then
- Refer for transplant evaluation
Diuretics: stop all if Na⁺ <125 mEq/L, AKI or worsening HE; K⁺ >5.5: stop spironolactone.
After an esophageal variceal bleed (no TIPS): NSBB plus EVL; hold NSBB if systolic BP <90, MAP <65 mmHg, AKI or Na⁺ <125 mEq/L.
Special Populations
| Population | Drug / Consideration | Specific Recommendation |
|---|---|---|
| Renal Impairment | Spironolactone / Furosemide | CrCl <30 mL/min: avoid spironolactone due to hyperkalemia risk; use furosemide alone with close electrolyte monitoring. If creatinine rises >2.0 mg/dL, hold all diuretics and evaluate for hepatorenal syndrome. Rifaximin does not require renal adjustment. |
| Hepatic Impairment | NSBB (Carvedilol, Propranolol) | Child-Pugh C: reduce carvedilol to 6.25 mg daily (no titration). Avoid propranolol in Child-Pugh C with refractory ascites due to reduced hepatic clearance and hemodynamic compromise. Discontinue NSBB if SBP <90 mmHg, MAP <65, AKI, or Na+ <125. |
| Elderly (≥65) | Diuretics / Lactulose | Start spironolactone at 50 mg/day (half the standard dose). Monitor for orthostatic hypotension and prerenal azotemia. Lactulose overuse causes dehydration-triggered encephalopathy in elderly — titrate cautiously. Fall risk assessment mandatory with encephalopathy. |
| Pregnancy | Spironolactone / NSBB | Spironolactone is contraindicated in pregnancy (anti-androgen effects, teratogenic). Use furosemide if diuretic necessary. Propranolol may be used cautiously (fetal bradycardia risk). Cirrhosis in pregnancy: high-risk obstetric care with GI/hepatology co-management mandatory. |
| Pediatric | Spironolactone / Lactulose | Spironolactone 1–3 mg/kg/day PO divided BID. Lactulose 1–2 mL/kg/dose PO BID–TID. Rifaximin: limited pediatric data; use in children ≥12 years at adult dosing. Biliary atresia is the most common cause of pediatric cirrhosis — Kasai portoenterostomy if diagnosed before 60 days of age. |
| HRS-AKI (Hepatorenal Syndrome with AKI) | Terlipressin or Norepinephrine + Albumin; Midodrine + Octreotide Only if Neither Is Available | For HRS-AKI only: vasoconstrictors and albumin are not recommended for HRS-NAKI (formerly HRS type II). Terlipressin is the first-line vasoconstrictor (NNT 5 for HRS reversal). Dose: 1 mg terlipressin acetate IV every 6 hours (one US vial contains 0.85 mg terlipressin, equivalent to 1 mg terlipressin acetate). US label: 1 vial every 6 hours on days 1 to 3; on day 4, if serum creatinine (SCr) has decreased by less than 30% from baseline, the dose may be increased to 2 vials (1.7 mg) every 6 hours; if SCr is at or above baseline, discontinue; continue until 24 hours after two consecutive SCr ≤1.5 mg/dL values at least 2 hours apart, or a maximum of 14 days. Boxed warning: terlipressin may cause serious or fatal respiratory failure, and patients with volume overload or ACLF grade 3 are at increased risk. Assess ACLF grade, volume status and SpO2 before starting; do not initiate in patients with hypoxia (e.g., SpO2 <90%) until oxygenation improves; monitor with continuous pulse oximetry and discontinue if SpO2 decreases below 90%. Contraindicated with hypoxia or worsening respiratory symptoms and with ongoing coronary, peripheral or mesenteric ischemia; avoid in ACLF grade 3 and in patients with a history of severe cardiovascular conditions, cerebrovascular and ischemic disease. Patients with SCr >5 mg/dL are unlikely to benefit, and in patients with high priority for liver transplantation (e.g., MELD ≥35) the benefits may not outweigh the risks. EASL recommends careful clinical screening including an electrocardiogram before starting terlipressin or norepinephrine. Consider norepinephrine (continuous infusion 0.5–3 mg/h) as the second-line agent if terlipressin is contraindicated or unavailable; it requires ICU care and central line placement. Midodrine 7.5 mg PO TID (titrate to 12.5 mg TID) plus octreotide 100 mcg SC TID can be an option only when neither terlipressin nor norepinephrine is available; its efficacy is much lower than that of terlipressin. Albumin (20–25%): 20–40 g/day, adjusted daily to volume status and stopped if there is evidence of volume overload. Hold diuretics; for volume overload during terlipressin, the US label advises reducing or stopping albumin and other fluids, judicious use of diuretics, and interrupting, reducing or stopping terlipressin until volume status improves. Renal replacement therapy as bridge to transplant only. |
Drug Interactions
| Drug | Interacting Agent | Mechanism | Clinical Effect | Management |
|---|---|---|---|---|
| Spironolactone | ACE inhibitors / ARBs / Potassium supplements | Combined RAAS blockade and potassium retention via aldosterone antagonism | Life-threatening hyperkalemia (K+ >6.0 mEq/L), cardiac arrhythmia | Avoid concurrent ACEi/ARB in cirrhotic patients on spironolactone. Check K+ every 3 days during initiation. Stop if K+ >5.5. |
| Propranolol / Carvedilol | Midodrine (for HRS) | Opposing hemodynamic effects: NSBB lowers cardiac output while midodrine raises MAP via alpha-1 agonism | Hemodynamic instability, unpredictable blood pressure, reflex bradycardia | Discontinue NSBB when initiating HRS treatment with midodrine/octreotide. Resume only after HRS resolution and stable hemodynamics. |
| Lactulose | Oral antibiotics (neomycin, metronidazole) | Antibiotics alter colonic bacterial flora needed to metabolize lactulose into organic acids that lower colonic pH | Reduced lactulose efficacy for ammonia trapping; paradoxical worsening of encephalopathy | Rifaximin is compatible with lactulose (synergistic). Avoid neomycin or systemic oral antibiotics that eliminate lactulose-metabolizing bacteria. |
| Rifaximin | Warfarin / Calcineurin inhibitors | Rifaximin is a weak P-glycoprotein inhibitor; minimal CYP3A4 induction at standard hepatic doses but may alter gut flora affecting vitamin K synthesis | Variable INR fluctuations; rare cyclosporine/tacrolimus level changes in post-transplant patients | Monitor INR weekly for first 4 weeks of rifaximin initiation in warfarin users. Check calcineurin inhibitor trough levels if adding rifaximin post-transplant. |
Liver cirrhosis means your liver has developed extensive scarring from long-term damage, which can come from alcohol use, fatty liver disease, or viral hepatitis. Your medical team will focus on managing fluid buildup in your abdomen with water pills and salt restriction, preventing dangerous bleeding from swollen veins in your esophagus with medication and sometimes endoscopic procedures, and keeping ammonia levels low to protect your brain function with lactulose and rifaximin. Regular ultrasound scans every 6 months check for liver cancer. If your liver disease continues to worsen, your doctors will evaluate whether you are a candidate for a liver transplant.
Complication management
Variceal prophylaxis, SBP and hepatorenal syndrome
Non-pregnant adults with cirrhosis.
If medium or large varices, or small with red wale signs or in Child‑Pugh C, before any bleed
Then
- NSBB, carvedilol preferred: 6.25 mg PO daily, titrate to max 12.5 mg daily; Child‑Pugh C: no titration
- Hold NSBB if systolic BP <90 mmHg, MAP <65 mmHg, AKI or Na⁺ <125 mEq/L
If ascitic PMN ≥250/mm³ (SBP), even if culture-negative
Then
- Community-acquired, low local resistance: ceftriaxone 2 g IV daily for 5–7 days
- Albumin 1.5 g/kg IV on day 1, then 1 g/kg IV on day 3
- After recovery: norfloxacin 400 mg or ciprofloxacin 500 mg PO daily
If HRS with acute kidney injury
Then
- Hold diuretics and NSBB; albumin 20–40 g/day, adjusted daily to volume status
- To start: terlipressin 1 mg IV q6h (preferred) or noradrenaline (central line); if neither is available: midodrine 7.5 mg PO TID + octreotide 100 mcg SC TID
- No terlipressin with hypoxia, worsening respiratory symptoms or ongoing coronary, peripheral or mesenteric ischemia; avoid in ACLF grade 3 or severe cardiovascular, cerebrovascular or ischemic disease
Terlipressin: monitor SpO₂ continuously and stop it if SpO₂ falls below 90%; in volume overload, reduce or stop albumin, fluids and terlipressin, and use diuretics judiciously.
EMA: avoid terlipressin with SCr ≥5.0 mg/dL or MELD ≥39 unless benefits outweigh risks.
Monitoring & Surveillance
Systematic monitoring in cirrhosis serves two purposes: tracking disease progression toward decompensation and detecting hepatocellular carcinoma at a curable stage. Every cirrhotic patient, regardless of etiology, requires HCC surveillance with abdominal ultrasound and serum alpha-fetoprotein (AFP) every 6 months. This remains the standard even after successful HCV eradication with direct-acting antivirals, as the risk of HCC persists in established cirrhosis. Additionally, monitoring must capture the dynamic changes in hepatic synthetic function (albumin, INR), portal hypertension markers (platelet count), renal function (creatinine, sodium), and treatment response parameters (body weight, encephalopathy grade). MELD score should be recalculated at every clinic visit in transplant-listed patients, as organ allocation priority depends on the most recent score. For patients on diuretics, electrolyte monitoring during titration prevents dangerous hypokalemia, hyperkalemia, and hyponatremia that can precipitate hepatorenal syndrome or encephalopathy.
- CBC with differential (platelet count)
- CMP: Na+, K+, Cr, BUN, albumin, bilirubin, AST, ALT, ALP
- INR / PT
- AFP (alpha-fetoprotein)
- Abdominal ultrasound with Doppler
- FibroScan (LSM) or FIB-4 if not already done
- Calculate MELD/MELD-Na and Child-Pugh score
- Serum Na+, K+, creatinine (hold diuretics if Cr >2.0 or Na+ <125)
- Body weight (target loss 0.5 kg/day without edema, 1 kg/day with edema)
- Blood pressure and heart rate (hold NSBB if SBP <90)
- CBC, CMP, INR (full panel)
- MELD/MELD-Na recalculation
- Encephalopathy assessment (psychometric hepatic encephalopathy score or Stroop test)
- Nutritional status and sarcopenia screen (grip strength, mid-arm circumference)
- Abdominal ultrasound + AFP for HCC surveillance (mandatory) A
- Variceal surveillance EGD is not part of this 6-month routine; its timing depends on the patient. On NSBB without EVL: no repeat EGD is needed unless clinically indicated. Compensated cirrhosis with Baveno VII low-risk criteria (LSM <20 kPa and PLT >150k): patients avoiding screening EGD can be followed with yearly FibroScan and platelet count and should undergo EGD if LSM increases to ≥20 kPa or PLT declines to ≤150k. Other patients not on NSBB, with no prior variceal bleeding or EVL: BSG 2015 suggests EGD at 2–3-year intervals if no varices were seen at the first endoscopy and yearly if grade I (small) varices without red signs were diagnosed; the clinician can modify these intervals if there is clear evidence of disease progression, and EGD should also be offered at the time of decompensation. Varices are generally a sign of clinically significant portal hypertension (CSPH), although after the cause of liver disease has been cured or controlled they may persist without CSPH; in compensated cirrhosis with CSPH, Baveno VIII recommends NSBB, particularly carvedilol, to prevent decompensation, so in these patients the yearly EGD interval for small varices is for those who cannot take NSBB (contraindication or intolerance). Varices that need primary prophylaxis are treated, not only watched: grade I varices with red signs or grade 2–3 varices (BSG 2015), small varices in Child-Pugh C, and varices of any size in a patient with ascites (Baveno VIII: carvedilol or a traditional NSBB; if these are not tolerated or contraindicated, endoscopic therapy alone should be considered). After EVL: follow the post-eradication EGD schedule in Step 2 (Responder).
- FibroScan / liver stiffness trending
Response & Safety Parameters
| Parameter | Target / Threshold | Frequency | Action if Abnormal |
|---|---|---|---|
| Serum sodium (Na+) | ≥130 mEq/L; alarm <125 mEq/L | Every 1–2 weeks during titration; q3 months stable | Na+ <125: stop diuretics, fluid restrict to 1–1.5 L/day; evaluate for HRS |
| Serum potassium (K+) | 3.5–5.0 mEq/L | Every 1–2 weeks during titration; q3 months stable | K+ >5.5: reduce/stop spironolactone. K+ <3.5: reduce furosemide, supplement KCl |
| Serum creatinine | <1.5 mg/dL; alarm >2.0 mg/dL | Every 1–2 weeks during titration; q3 months stable | Cr >2.0 or rise >0.3 in 48h: hold diuretics, assess volume status; if volume-depleted, resuscitate with crystalloids first-line (preferentially balanced solutions) unless another fluid is specifically indicated, and if volume status is equivocal, a fluid challenge (250–500 mL of crystalloid or 1–1.5 g/kg of 20–25% albumin) may be given; do not give 48 h of albumin to euvolemic or fluid-overloaded patients; rule out HRS |
| AFP (alpha-fetoprotein) | <20 ng/mL (normal); alarm >200 ng/mL | Every 6 months with ultrasound | AFP ≥20: triphasic CT or MRI liver. AFP >200 with arterially enhancing lesion: presumptive HCC diagnosis |
| MELD score | Track trend; alarm ≥15 | Every clinic visit (q3 months minimum) | MELD ≥15: initiate transplant referral. MELD ≥21: 3-month mortality >20%, expedite listing |
| Platelet count | >50,000/mcL (procedure threshold) | Every 3 months | PLT <50,000: hold elective procedures; consider thrombopoietin agonist (avatrombopag 60 mg PO daily x 5 days) before scheduled procedure |
Clinical Commentary
Interventional radiology / TIPS consultation: Patients requiring ≥3 large-volume paracenteses per month (refractory ascites), recurrent variceal bleeding despite EVL + NSBB, or Budd-Chiari syndrome refractory to anticoagulation. In acute variceal bleeding, also consult for patients who meet the preemptive TIPS criteria (Treatment Algorithm, Step 2; PTFE-covered TIPS within 72 hours), for patients bleeding from GOV2 or IGV1, in whom TIPS with or without variceal embolization, performed as soon as possible, is the preferred definitive treatment option (Treatment Algorithm, Step 2), and when bleeding is not controlled despite combined pharmacological and endoscopic therapy (salvage PTFE-covered TIPS).
Hepatology/oncology referral for HCC: Any new hepatic lesion ≥1 cm on surveillance ultrasound requires triphasic CT or MRI. AFP >200 ng/mL with compatible imaging warrants multidisciplinary tumor board review. Milan criteria assessment (single lesion ≤5 cm or up to 3 lesions each ≤3 cm) for transplant eligibility.
ICU transfer criteria: Variceal hemorrhage with hemodynamic instability (SBP <90, HR >120) or hemoglobin drop >2 g/dL in 24 hours. Grade III–IV hepatic encephalopathy (obtundation, coma). Acute-on-chronic liver failure (ACLF) with ≥2 organ failures. HRS with oliguric AKI unresponsive to albumin challenge.
- Optimal timing and criteria for withdrawing non-selective beta-blockers in advanced decompensated cirrhosis remain debated, with no randomized trials defining the precise hemodynamic threshold for discontinuation
- The role of long-term albumin infusion (weekly IV albumin) for all decompensated cirrhosis patients outside of SBP and LVP settings is under active investigation, with the ANSWER trial suggesting mortality benefit but confirmation needed
- Whether the addition of simvastatin to standard therapy reduces portal pressure and improves outcomes in compensated cirrhosis is an emerging question from pilot data showing HVPG reduction D
- Direct oral anticoagulants (DOACs) for portal vein thrombosis in cirrhosis lack large randomized trials; current use is extrapolated from smaller studies showing acceptable safety profiles
Practice Insights: What Drives Bedside Decisions in Cirrhosis
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)In routine hepatology and inpatient medicine practice, the Baveno VII consensus shifted cirrhosis care from endoscopy-first to non-invasive risk stratification (FibroScan plus platelet count) for primary prophylaxis decisions, and carvedilol has emerged as the preferred non-selective beta-blocker over propranolol based on Villanueva 2019 mortality data. Decompensation is most clearly delayed in patients identified at the clinically significant portal hypertension (CSPH) stage through non-invasive criteria and started on carvedilol primary prophylaxis before any decompensation event.
What the Guideline Misses
Carvedilol is preferred over propranolol as non-selective beta-blocker for portal hypertension prophylaxis based on Villanueva 2019 individual-patient meta-analysis demonstrating mortality and decompensation reduction. Carvedilol’s additional alpha-1 antagonism reduces intrahepatic vascular resistance beyond what beta-blockade alone achieves. A defensible standard is carvedilol 6.25 mg once daily, increased to a maintenance dose of 12.5 mg/day after a week if tolerated (the optimum dose is 6.25–12.5 mg/day; higher doses are not more effective and are associated with more adverse events, in particular hypotension), with propranolol reserved for carvedilol intolerance.
Patterns That Recur
Albumin under-dosed during large-volume paracentesis is the practice gap that most often needs correcting in inpatient settings. The evidence-based dose is 8 grams of albumin per liter of ascitic fluid removed when paracentesis exceeds 5 L, preventing post-paracentesis circulatory dysfunction. Many institutional protocols use lower doses or omit albumin entirely for “small large-volume” paracentesis around 5-7 L, missing the prevention of renal injury and hyponatremia that proper dosing produces.
A Practical Bedside Heuristic
The Baveno VII CSPH rule-in criterion — a liver stiffness measurement (LSM) by transient elastography of ≥25 kPa in virus- or alcohol-related and non-obese (BMI <30 kg/m²) NASH-related compensated advanced chronic liver disease — identifies the population that benefits from non-selective beta-blocker primary prophylaxis without requiring screening endoscopy in many cases. The historical “EGD first to look for varices, then NSBB if varices present” pathway is being replaced by the non-invasive risk-based pathway, particularly in advanced compensated cirrhosis where the CSPH probability is high. The either-or rule of LSM ≥20 kPa or a platelet count ≤150,000/mcL is not the CSPH rule-in: Baveno VII uses it as the threshold for screening endoscopy in patients who are not candidates for NSBBs. In the same etiologies with LSM <25 kPa, the ANTICIPATE model estimates a CSPH risk of at least 60% for LSM 20–25 kPa with platelets <150,000/mcL or LSM 15–20 kPa with platelets <110,000/mcL, and there is no indication at present to use NSBBs in patients without CSPH.
Transplant Referral Principles
Transplant referral at MELD-Na 15 or higher, or at any decompensation event (ascites, variceal bleed, hepatic encephalopathy, HCC), rather than waiting for the patient to “be sicker.” The transplant evaluation process takes months, and earlier referral preserves the option of preemptive transplantation before life-threatening decompensation. The first decompensation is best treated as the transplant evaluation trigger regardless of MELD score.
Illustrative Scenario
A man in his late sixties with alcohol-related cirrhosis Child-Pugh B (score 8) and MELD-Na 14 was identified at outpatient hepatology clinic. Liver stiffness measurement by FibroScan was 32 kPa, platelet count was 88,000/mm³, and serum bilirubin was 2.4 mg/dL. He met Baveno VII CSPH criteria, and primary non-selective beta-blocker prophylaxis was initiated with carvedilol 6.25 mg once daily, increased to 12.5 mg/day after a week if tolerated, without proceeding to screening endoscopy first, per Baveno VII risk-based pathway. Three months later he developed new ascites; spironolactone 100 mg + furosemide 40 mg daily was initiated, with diuretic titration over 4 weeks. At month 6 he required first large-volume paracentesis of 6 L, dosed with albumin 8 g per liter removed (total 48 g of 25% albumin IV post-procedure) per evidence-based protocol. At month 9 he developed his first episode of spontaneous bacterial peritonitis confirmed on diagnostic paracentesis (PMN count 380), treated with cefotaxime 2 g IV every 8 hours for 5 days plus albumin 1.5 g/kg on day 1 and 1 g/kg on day 3 per IRA prevention protocol, with norfloxacin 400 mg daily secondary prophylaxis on discharge. Hepatic encephalopathy episode at month 11 managed with lactulose plus rifaximin 550 mg twice daily. Transplant evaluation referral was initiated at first decompensation; he was listed at month 12 and underwent successful deceased-donor liver transplantation at month 15.
Protocol Adjustments to the Standard Pathway
- Carvedilol over propranolol as preferred NSBB for portal hypertension per Villanueva 2019 meta-analysis demonstrating mortality and decompensation reduction. Starting dose 6.25 mg once daily, increased to a maintenance dose of 12.5 mg/day after a week if tolerated; higher doses are not more effective and are associated with more adverse events, in particular hypotension.
- Albumin 8 g per L removed for large-volume paracentesis >5 L, preventing post-paracentesis circulatory dysfunction. SBP: albumin 1.5 g/kg day 1 and 1 g/kg day 3 prevents IRA. HRS-AKI: albumin 20-40 g daily with the vasoconstrictor, adjusted daily to volume status and stopped if there is evidence of volume overload.
- Baveno VII CSPH rule-in (LSM by transient elastography ≥25 kPa in virus- or alcohol-related and non-obese NASH-related compensated advanced chronic liver disease) → primary NSBB prophylaxis without requiring screening endoscopy in selected patients, replacing the older endoscopy-first pathway for advanced compensated cirrhosis. LSM ≥20 kPa or platelets ≤150 is the screening-endoscopy threshold for patients who are not NSBB candidates, not the CSPH rule-in, and there is no indication at present for NSBBs without CSPH.
- Transplant referral at MELD-Na ≥15 OR first decompensation event, not waiting for “sicker.” Transplant evaluation takes months; earlier referral preserves preemptive transplant option before life-threatening decompensation.
Baveno VII
Non-invasive CSPH triage in compensated cirrhosis
If LSM ≥25 kPa by transient elastography; viral, alcohol-related or non-obese NASH cause
Then
- CSPH ruled in: NSBB, no screening EGD needed in selected patients
- Carvedilol preferred: 6.25 mg once daily, 12.5 mg/day (max) after a week if tolerated
- Hold NSBB if systolic BP <90, MAP <65 mmHg, AKI or Na⁺ <125 mEq/L
If not on NSBB for CSPH, with LSM ≥20 kPa or platelets ≤150,000/mcL
Then
- Screening EGD; NSBB per Step 2 if a candidate
Otherwise: LSM <20 kPa and platelets >150,000/mcL: very low risk of high-risk varices, no screening EGD
No indication at present for NSBBs without CSPH.
Frequently Asked Questions
- Drug-Induced Liver Injury: ACG and EASL Diagnosis with R-Ratio Hy’s Law RUCAM Causality and N-Acetylcysteine Management
- Hepatopulmonary Syndrome: Contrast Echo Diagnosis, MELD Exception, and Liver Transplant Outcomes
- Acute Liver Failure: Diagnosis, Etiology Workup, NAC, and King’s College Transplant Criteria
- Hemorrhoids: ACG/ASCRS Diagnosis, Goligher Grading, and Office vs Surgical Management
- Budd-Chiari Syndrome: AASLD Diagnostic Algorithm, Stepwise Therapy, and TIPS vs Liver Transplantation
- Acute Appendicitis: WSES and EAES Diagnosis with Alvarado AIR Score CT Imaging and Laparoscopic Appendectomy
Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.
- AASLD 2021 Guidance: ascites, SBP and hepatorenal syndrome in cirrhosis (Hepatology · 2021)
- EASL 2018 CPG for decompensated cirrhosis (Journal of Hepatology · 2018)